{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:07Z","timestamp":1792839667514,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jhep.2021.08.024","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:05:32Z","timestamp":1630667132000},"page":"86-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment"],"prefix":"10.1016","volume":"76","author":[{"given":"Helgi Kristinn","family":"Bj\u00f6rnsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar Stefan","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jhep.2021.08.024_bib1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury - types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N\u00a0Engl J Med 2019\/07\/18"},{"issue":"12","key":"10.1016\/j.jhep.2021.08.024_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann Intern Med."},{"issue":"5","key":"10.1016\/j.jhep.2021.08.024_bib3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver injury from tumor necrosis factor-\u03b1 antagonists: analysis of thirty-four cases","volume":"11","author":"Ghabril","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2021.08.024_bib4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"Risk of drug-induced liver injury from tumor necrosis factor antagonists","volume":"13","author":"Bjornsson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2021.08.024_bib5","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","article-title":"Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids","volume":"15","author":"Bjornsson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.08.024_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Features of autoimmune hepatitis in patients with drug-induced liver injury","volume":"15","author":"de Boer","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2021.08.024_bib7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.cgh.2016.08.011","article-title":"Reply","volume":"14","author":"De Boer","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2021.08.024_bib8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2021.08.024_bib9","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1007\/s10620-018-5023-6","article-title":"Acute liver failure from tumor necrosis factor-\u03b1 antagonists: report of four cases and literature review","volume":"63","author":"Kok","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.jhep.2021.08.024_bib10","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000134","article-title":"Now you see it, now you do not: a case of infliximab-induced vanishing bile duct syndrome","volume":"6","author":"Shah","year":"2019","journal-title":"ACG Case Reports J"},{"issue":"24","key":"10.1016\/j.jhep.2021.08.024_bib11","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J Gastroenterol WJG"},{"issue":"11","key":"10.1016\/j.jhep.2021.08.024_bib12","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1007\/s10620-013-2698-6","article-title":"Infliximab-related hepatitis: a\u00a0case study and literature review","volume":"58","author":"Colina","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.jhep.2021.08.024_bib13","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/rheumatology\/keu252","article-title":"Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO","volume":"53","author":"Glintborg","year":"2014","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.jhep.2021.08.024_bib14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.jhep.2021.08.024_bib15","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/ng.3964","article-title":"Graphtyper enables population-scale genotyping using pangenome graphs","volume":"49","author":"Eggertsson","year":"2017","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.jhep.2021.08.024_bib16","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/ng.216","article-title":"Detection of sharing by descent, long-range phasing and haplotype imputation","volume":"40","author":"Kong","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2021.08.024_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41397-020-0159-0","article-title":"HLA associations with infliximab-induced liver injury","author":"Bruno","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jhep.2021.08.024_bib18","series-title":"Health NI of. Livertox: clinical and research information on drug-induced liver injury","year":"2012"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.024_bib19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports","volume":"63","author":"Bjornsson","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2021.08.024_bib20","doi-asserted-by":"crossref","first-page":"102460","DOI":"10.1016\/j.autrev.2020.102460","article-title":"Characterization of auto-immune hepatitis associated with the use of anti-TNF\u03b1 agents: an analysis of 389 cases in VigiBase","volume":"19","author":"Vollmer","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.jhep.2021.08.024_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"van Gerven","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2021.08.024_bib22","first-page":"401","article-title":"Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-a blockers","volume":"26","author":"Gonnet-Gracia","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.08.024_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2021.08.024_bib24","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2021.08.024_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cgh.2010.07.016","article-title":"Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis","volume":"9","author":"Bj\u00f6rnsson","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2021.08.024_bib26","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jhep.2018.05.013","article-title":"Pharmacogenomics of drug-induced liver injury (DILI): molecular biology to clinical applications","volume":"69","author":"Kaliyaperumal","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2021.08.024_bib27","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study","volume":"152","author":"Nicoletti","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2021.08.024_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/00365521.2017.1420218","article-title":"Low prevalence of hepatitis E in Iceland: a seroepidemiological study","volume":"53","author":"Love","year":"2018","journal-title":"Scand J Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821020225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821020225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:44:03Z","timestamp":1759175043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821020225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0168827821020225"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.08.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}